Hybrid Shell for Clinical Applications
Author Information
Author(s): Philippe Dandoy, Christophe F. Meunier, Carine Michiels, Bao-Lian Su
Primary Institution: The University of Namur (FUNDP), Belgium
Hypothesis
Can a silica-alginate hybrid shell protect mammalian cells and maintain their functionality for drug delivery?
Conclusion
The study demonstrates that HepG2 cells can be effectively encapsulated in a silica-alginate hybrid shell, maintaining their viability and functionality for over six weeks.
Supporting Evidence
- The mineralized beads showed a high survival rate of HepG2 cells over six weeks.
- The encapsulation method preserved the physiological functions of the cells.
- The hybrid beads allowed for the diffusion of nutrients and therapeutic agents.
Takeaway
Scientists created a special shell to protect cells so they can help deliver medicine in the body without getting hurt.
Methodology
The study involved designing and synthesizing biocompatible mineralized beads with a silica-alginate composite core and a Ca-alginate layer, followed by testing their cytotoxicity and immune response.
Limitations
The study primarily focused on in vitro conditions, and further in vivo studies are needed to confirm the findings.
Participant Demographics
Human hepatocellular carcinoma cell line (HepG2) was used as the model cell.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website